百令胶囊治疗呼吸系统疾病有效性的系统评价
x

请在关注微信后,向客服人员索取文件

篇名: 百令胶囊治疗呼吸系统疾病有效性的系统评价
TITLE:
摘要: 目的:系统评价百令胶囊治疗呼吸系统疾病的有效性,为临床提供循证参考。方法:计算机检索中国期刊全文数据库、中国学位论文全文数据库、万方数据库、中文科技期刊数据库、Cochrane图书馆、Medline(Ebsco)和PubMed,收集百令胶囊联合常规治疗方案(试验组)对比单纯常规方案(对照组)治疗呼吸系统疾病的随机对照试验(RCT),提取资料并按照修改后的Jadad评分量表和Cochrane偏倚风险评估量表评价纳入研究质量,采用Rev Man 5.2统计软件进行Meta 分析。结果:共纳入17项RCT,合计1 801例患者。Meta分析结果显示,试验组患者有效率[RD=0.15,95%CI(0.10,0.19),P<0.001] 、第1秒用力呼气量容积(FEV1)水平[MD=0.21,95%CI(0.14,0.28),P<0.001]。用力吸气肺活量(FVC)水平[MD=0.26,95%CI(0.05,0.47),P=0.01]、FEV1/FVC水平[MD=5.60,95%CI(3.42,7.78),P<0.001]显著高于对照组,差异均有统计学意义。结论:百令胶囊治疗呼吸系统疾病疗效较好,可以显著改善患者肺部相关指标。
ABSTRACT: OBJECTIVE: To evaluate the effectiveness of Corbrin capsules for respiratory systemdisease  systematically,in order to provide evidence-based reference for clinical use. METHODS: Retrieved from CJFD,China Dissertation Database,Wanfang database,VIP,Cochrane Library,Medline and PubMed,randomized controlled trials (RCTs) about conventional treatment plan (trial group) vs. single treatment plan (control group) in the treatment of respiratory system disease. The quality of included studies were evaluated after extracting data and modifying according to Jadad scale and Cochrane bias risk assessment scale. Meta-analysis was performed by using RevMan 5.2 statistical software. RESULTS: A total of 17 RCTs were included,involving 1 801 patients. The results of Meta-analysis showed that response rate [RD=0.15,95%CI(0.10,0.19),P<0.001],FEV1[MD=0.21,95%CI(0.14,0.28),P<0.001],FVC [MD=0.26,95%CI(0.05,0.47),P<0.001] and FEV1/FEV [MD=5.60,95%CI(3.42,7.78),P<0.001] of trial group were significantly higher than those of control group,with statistical significance.   CONCLUSIONS: Corbrin capsules have good therapeutic efficacy for respiratory system disease and effectively improve lung related indicators.
期刊: 2017年第28卷第18期
作者: 张亚同,刘泽辉,胡欣
AUTHORS: ZHANG Yatong,LIU Zehui,HU Xin
关键字: 百令胶囊;呼吸系统;有效性;系统评价; Meta分析
KEYWORDS: Corbrin capsules; Respiratory system disease; Effectiveness; Systematic evaluation; Meta-analysis
阅读数: 419 次
本月下载数: 12 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!